Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
4M
Biotechnology
Next Earning date - 06 Mar 2025
4M
Biotechnology
Next Earning date - 06 Mar 2025
Relative Strenght
7Volume Buzz
-98%Earning Acce
YesDist 52w H.
92%